Why Longitudinal HealthTech is Poised to Win Big when CMS enforces its Mandatory Transforming Episode Accountability Model in 2026

As the U.S. healthcare system pivots toward greater efficiency, cost containment, and patient-centered care, a seismic transformation is taking shape that promises to redefine medical technology’s role in the surgical episode lifecycle. At the heart of this shift lies the Transforming Episode Accountability Model (TEAM)—a mandatory, five-year model launching on January 1, 2026, under the direction of the Centers for Medicare & Medicaid Services (CMS). Designed to reshape how hospitals coordinate care and are reimbursed for it, TEAM may prove to be a watershed moment—not only for providers but for AI-driven medical device innovators who’ve spent the last decade laying the groundwork for just such a system. Among the technologies poised to emerge as clear winners as a result of this significant policy shift are the TrabeculeX Continuum by Xenco Medical, the VELYS digital ecosystem by Johnson and Johnson, and the myMobility + PersonaIQ platforms by ZimmerBiomet. 

The TrabeculeX Continuum, the VELYS digital ecosystem, and the myMobility + PersonaIQ platforms represent a technological embodiment of the TEAM model’s core objectives—coordinated, value-based, longitudinal care. As CMS gears up to launch TEAM, the structural redesign of care delivery may very well cement a fundamental, systemic advantage for companies with these kinds of uniquely longitudinal technologies at the forefront of their industry. 

Understanding the TEAM Model: A Paradigm Shift

TEAM is not a suggestion; it’s a mandatory model for acute care hospitals located in selected Core-Based Statistical Areas (CBSAs). Hospitals in these regions will be held accountable for the cost and quality of care delivered during a surgical episode, defined as beginning with hospitalization and ending 30 days after discharge.

The five included surgical procedures—spinal fusion, lower extremity joint replacement, surgical hip/femur fracture treatment, coronary artery bypass graft (CABG), and major bowel procedures—are some of the most common and cost-intensive interventions covered by Medicare. Under TEAM, hospitals are given a target price based on historical spending and must stay within this budget while meeting strict quality benchmarks.

Failure to manage post-discharge complications, readmissions, or lapses in care coordination will result in financial penalties, while success is rewarded with shared savings.

This creates a radical shift away from the traditional fee-for-service (FFS) model, where fragmentation often leads to inflated costs and poor outcomes. Instead, CMS’s TEAM model incentivizes providers to think beyond the operating room—to consider a patient’s entire recovery journey.

Why Traditional Device Companies May Struggle Under TEAM

Conventional medical device companies, focused predominantly on intraoperative performance and procedural revenue, may find the new model challenging. In the TEAM framework, outcomes matter more than units sold. Devices that perform well in isolation but lack any post-op engagement tools are ill-suited for a model that evaluates longitudinal value.

Under TEAM, it’s not just about how the implant performs in surgery—it’s about how the patient recovers afterward, and whether the intervention leads to cost-effective, high-quality care in the days and weeks that follow. Most legacy players in the medical device space offer minimal engagement post-discharge, making it harder for hospitals to meet CMS’s new accountability standards.

The Rising Dominance of Tech-Centered Longitudinal Care

Xenco Medical, twice named one of the World’s Most Innovative Companies by Fast Company Magazine has led with a vision of healthcare that aligns in synchrony with the TEAM model’s demands. 

At the heart of the renowned company’s longitudinal offerings is its AI-enabled TrabeculeX Continuum, a braided platform that merges regenerative biomaterial implantation with an AI-driven, remote physical rehabilitation program. The groundbreaking harmonization of biomaterials and digital health in the company’s technology forms a continuous care platform that not only accelerates recovery but also addresses one of the most persistent problems in medicine: siloed care.

In doing so, Xenco Medical has created an ecosystem of care that seemingly anticipated TEAM’s requirements. The CMS policy will require hospitals to coordinate everything from surgery to rehab. TrabeculeX covers this gamut by enabling remote therapeutic monitoring of every patient implanted with its orthobiologic, offering 1600 AI-powered rehabilitation exercises personalized to the patient’s pathology and the surgeon’s guidance. TEAM penalizes hospitals for costly readmissions. Xenco Medical’s groundbreaking technology helps mitigate this risk by allowing real-time pain scoring, posture analysis, and rehab adherence tracking—ensuring issues are caught before they escalate. After the biomaterial implantation phase, it effectively turns the patient’s own devices into a virtual care companion—helping hospitals standardize pathways, reduce readmissions, and keep patients engaged beyond discharge. CMS evaluates participants on a range of quality measures, including patient-reported outcomes, readmission rates, and adverse events. By enabling a closed-loop feedback system between surgeon and patient that incorporates its synthetic alternative to human bone, Xenco helps hospitals meet these measures and maximize incentives.

The VELYS digital ecosystem by Johnson and Johnson offers an integrated platform that spans the entire patient journey, from pre-op readiness through post-op recovery. VELYS Patient Path drives patient engagement with personalized education, remote monitoring, and coordinated communication, while VELYS Insights streamlines workflow and supports data-driven care coordination. These tools address key TEAM success factors: standardizing care pathways, aligning providers, and managing performance against quality benchmarks. By helping hospitals reduce avoidable post-acute spending and prevent readmissions—without sacrificing patient experience—VELYS aligns directly with CMS’s goals.

In the operating room, the VELYS Robotic-Assisted Solution enhances surgical precision and reproducibility, reducing variability that often drives up episode costs. Better implant positioning and soft-tissue balancing can shorten hospital stays, lower complication rates, and minimize downstream utilization—outcomes that matter more than ever under TEAM’s mandatory bundled payment model with built-in discount factors. With recent FDA clearance for unicompartmental knee applications, the system’s clinical reach is also expanding.

The shift to TEAM will require hospitals to produce clean, comprehensive data across the care continuum. VELYS’s unified digital infrastructure—integrating education, monitoring, and team communication—makes that easier while enabling real-time performance management. In a value-based future where precision, coordination, and measurable outcomes drive reimbursement, Johnson & Johnson’s VELYS platform is a strategic asset. TEAM may be the policy push that accelerates its adoption.

ZimmerBiomet’s myMobility + PersonaIQ  uses the iPhone and Apple Watch to deliver personalized pre- and post-operative guidance, collect patient-reported outcomes, and monitor activity levels in real time. The platform directly supports TEAM’s quality benchmarks, while also generating the longitudinal data needed for CMS reporting.

PersonaIQ in particular, the first FDA-cleared smart knee implant with an embedded sensor, takes remote monitoring a step further. It automatically captures key functional metrics—like range of motion and step count—from inside the joint, transmitting them securely to the care team. This inside-out view of recovery allows providers to detect setbacks earlier, personalize rehab, and reduce costly complications. In a TEAM environment, where post-acute costs and preventable readmissions can make or break margins, that level of continuous insight could prove invaluable.

Together, mymobility and PersonaIQ create a closed feedback loop: patient adherence and functional recovery are tracked seamlessly, care plans can be adjusted in near real time, and outcomes can be documented with objective data. As TEAM drives hospitals to prove value across the episode, the Zimmer Biomet ecosystem offers both the engagement tools and the hard metrics to succeed. In short, CMS is raising the bar on accountability, and mymobility plus PersonaIQ gives providers the tech to clear it.

Economic and Policy Timing Couldn’t Be Better

The launch of TEAM in January 2026 comes at a time when healthcare economics are under intense scrutiny. In this high-stakes environment, CMS is betting that episode-based payment and value-driven care coordination will bend the cost curve in the right direction.

But value-based models only succeed when technology enables them. That’s where these three companies stand apart—offering a solution born from an understanding that value must be tracked, measured, and digitally extended beyond the operating room.

The Broader Implications for AI in Healthcare

TEAM isn’t just a model—it’s a signal. As the largest payer in the country, CMS is clearly endorsing a future where AI and digital technologies aren’t add-ons but necessities. Remote monitoring, predictive analytics, and personalized rehabilitation aren’t just buzzwords—they’re vital infrastructure for success under TEAM.

While traditional devices may flounder to adapt, Xenco Medical‘s TrabeculeX Continuum, Johnson and Johnson’s VELYS digital ecosystem, and ZimmerBiomet‘s myMobility + PersonaIQ, with AI and data embedded in their DNA, are set to leapfrog the competition.

Final Thoughts: The Future is Longitudinal

The mandatory nature of TEAM, coupled with its emphasis on full-episode accountability, will challenge the status quo of the medical device industry. Companies that cling to isolated, intraoperative-only approaches will find themselves outpaced by those who understand that value lies in the entire patient journey. As 2026 approaches, healthcare leaders, providers, and investors would be wise to watch this space.